PROX1 is a predictor of survival for gliomas WHO grade II by Elsir, T et al.
PROX1 is a predictor of survival for gliomas WHO grade II
T Elsir
1,6,MQ u
1,2,5,6, SG Berntsson
2, A Orrego
1, T Olofsson
3, MS Lindstro ¨m
1, M Niste ´r
1, A von Deimling
4,
C Hartmann
4, D Ribom
2 and A Smits*,2
1Department of Oncology-Pathology, Karolinska Institutet, CCK R8:05, Karolinska University Hospital, S-17176 Stockholm, Sweden;
2Department of
Neuroscience, Neurology, Uppsala University, S-75185 Uppsala, Sweden;
3National Board of Forensic Medicine, S-75140 Uppsala, Sweden;
4Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, and Clinical Cooperation Unit Neuropathology, German
Cancer Research Center, 69120 Heidelberg, Germany
BACKGROUND: The clinical course of World Health Organisation grade II gliomas remains variable and their time point of
transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in
individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs.
PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that
PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in
grade II gliomas.
METHODS: A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used
as a variable in survival analysis, together with established prognostic factors for this patient group.
RESULTS: Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an
independent factor for survival (P¼0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and
with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.
CONCLUSION: PROX1 is a novel predictor of survival for grade II gliomas.
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Adult low-grade gliomas (LGG) are poorly circumscribed diffusely
infiltrative brain tumours localised mainly in the cerebral hemi-
spheres. They affect otherwise healthy individuals with an average
age of B40 years at the time of diagnosis. Low-grade gliomas
in adults are classified as grade II gliomas according to the World
Health Organisation (WHO) classification of brain tumours and
consist mainly of astrocytomas, oligodendrogliomas and oligoas-
trocytomas (Louis et al, 2007). The median survival for LGG is
5–10 years, but clinical outcome varies considerably (Lote et al,
1997). For some patients the disease has an indolent course for
many years, whereas others experience rapid tumour progression
from the time of diagnosis. Treatment is unsatisfactory and there is
no cure for LGG (Soffietti et al, 2010). There is consensus but no
evidence that maximal surgical resection prolongs survival in LGG
(Keles et al, 2001; Duffau, 2009). A large randomised trial designed
to define the optimal timing of radiotherapy showed a prolonged
symptom-free survival for patients with LGG receiving adjuvant
radiotherapy compared with those irradiated at progression, but
no difference in overall survival (Karim et al, 2002; van den Bent
et al, 2005).
For optimal patient management, clinical parameters with an
impact on survival have to be taken into account (Pignatti et al,
2002; Soffietti et al, 2010). Negative prognostic factors for survival
are old age, astrocytoma histology, neurological deficit at
presentation, large tumour diameter, contrast enhancement and
tumours crossing midline (Pignatti et al, 2002). The presence of
two or less unfavourable factors identifies low-risk groups, and for
these low-risk patients it is probably a good strategy to defer
radiotherapy until tumour progression (Pignatti et al, 2002). Many
treatment decisions, however, remain unsolved. The clinical
management of patients with LGG will benefit from prognostic
and predictive biomarkers that can guide therapeutic decisions.
One such example is the combined loss of chromosomal arms
1p/19q, the molecular hallmark of oligodendrogliomas and a
strong prognostic and predictive marker in these tumours (Ohgaki
and Kleihues, 2005).
PROX1 is a transcription factor expressed in the heart, liver,
lens, skeletal muscles, pancreas, kidney and in the CNS (Zinovieva
et al, 1996). The Drosophila homologue of PROX1, prospero,
resembles a tumour suppressor gene by preventing neuroblast self-
renewal. In the absence of prospero, cells accumulate forming
brain tumours (Betschinger et al, 2006). It has been suggested that
PROX1 has a similar role in human malignancies. Decreased
expression of PROX1 was found in hepatocellular carcinomas,
sporadic breast cancer and carcinomas of the biliary system
(Shimoda et al, 2006; Laerm et al, 2007; Versmold et al, 2007). In
contrast, PROX1 was overexpressed in colorectal cancer and found
to have a role in promoting cancer progression (Petrova et al,
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s2008). We have recently shown that PROX1 protein is over-
expressed in human astrocytic tumours, with highest levels in
grade III and IV astrocytomas (Elsir et al, 2010). These findings
suggest that PROX1 may act as a prognostic factor in human
gliomas. In the present study, we have studied the presence of
PROX1 protein in correlation with patient survival in a cohort of
patients with LGG.
MATERIALS AND METHODS
Tumour samples
Tumour samples with primary histopathological diagnosis of
supratentorial WHO grade II glioma were collected from patients
aged X16 years operated between January 1982 and December
1999 at neurosurgery, Uppsala University Hospital. The ethics
committee approved the study protocol and recruitment of
patients was based on informed consent. A total number of
152 paraffin-embedded tumour blocks were identified and pre-
examined by a neuropathologist (TO) to verify representative
tumour material. Samples were then sectioned and evaluated by
the review neuropathologist (AO), who had not been involved in
the primary diagnosis. Tumours were classified as astrocytomas
(including gemistocytic astrocytomas), oligodendrogliomas and
oligoastrocytomas grade II according to the WHO classification of
brain tumours (Louis et al, 2007). Representative areas in the
tumour bulk, consisting of predominantly tumour cells (480%)
compared with normal cells, were marked on each slide. Pilocytic
astrocytomas, gangliogliomas, pleomorphic xanthoastrocytomas
and tumours with signs of anaplasia were excluded (n¼23). Nine
samples were of poor technical quality, leaving 120 tumours.
Collection of clinical data
A retrospective chart review was performed for all 120 cases. In
four cases, medical files were incomplete and clinical data could
not be evaluated, and a total of 116 cases were included in the
present study. The following data were collected from the patient
records and from CT or MRI scans of the brain: time point of first
symptoms, patient age at disease onset, date of operation, date of
death, tumour size, tumour location (specific lobe and (sub)-
cortical or central location), the presence of contrast enhancement,
preoperative performance status according to Karnofsky Perfor-
mance Status, date and extent of diagnostic surgery (biopsy,
subtotal or gross total resection). The extent of tumour resection
was based on postoperative CT scans or on the surgeon’s operative
notes.
Survival was defined as the time point between first symptoms
and date of death or end of the study (20 September 2009). Data
concerning time of death and the cause of death were collected
from central health authorities (the National Cause of Death
Register Data).
Validation of PROX1 antibodies
For expression analysis, we evaluated two commercially available
anti-PROX1 antibodies, one goat (R&D Systems, Minneapolis, MN,
USA; diluted 1:100) and one rabbit polyclonal (ab11941; Abcam,
Cambridge, UK; diluted 1:100), raised against the N-terminus and
C-terminus of PROX1, respectively. Validation of the sensitivity
and specificity of the antibodies was tested previously (Elsir et al,
2010). In summary, we tested the antibodies by using SW480 colon
carcinoma cells, known to express PROX1, and U2OS osteosarco-
ma cells, used as a negative control (Petrova et al, 2008). Immuno-
staining by the immunofluorescence technique showed negative
staining for the U2OS cells and an identically strong nuclear
PROX1 staining in SW480 cells for both antibodies. We then used
PROX1 siRNA to knock out gene expression from the SW480 cells
and overexpressed PROX1 cDNA in the negative cell line U2OS.
Immunostaining subsequent to these techniques further confirmed
the specificity of the antibodies, in agreement with published
findings on PROX1 protein (Petrova et al, 2008).
PROX1 immunostaining
Immunostaining with anti-PROX1 antibodies was performed on
formalin-fixed and paraffin-embedded sections using the Ventana
Discovery Automated Stainer (Ventana Medical Systems, Tucson,
AZ, USA), following Vendor’s instructions. Deparaffinisation took
place in the Ventana machine and the heat-induced epitope
retrieval incubation was performed in Tris-Borate EDTA buffer
pH 8.0. Primary antibody was a goat anti-PROX1 antibody (R&D
System), purchased commercially and diluted 1:100 in 1% BSA,
0.1% Tween-20 in PBS. A streptavidin-biotin horseradish perox-
idase based DAB kit provided by Ventana was used for detection of
immunoreactivity. Secondary antibody was a polyclonal biotiny-
lated rabbit anti-goat (Dako E0466, Dako Sweden AB, Stockholm,
Sweden) diluted at 1:500 in Ab-diluent (Ventana Medical
Systems). Sections were counterstained with haematoxylin. Finally,
slides were subjected to graded ethanol rinses, cleared in Xylene
and mounted in Pertex. Sections from a glioblastoma case, known
to express high levels of PROX1, were added as a positive control
in each Ventana run.
Detection of mutated IDH1 R132H protein
Mutated isocitrate dehydrogenase 1 (IDH1) R132H protein was
detected using a monoclonal mouse antibody targeting the
mutated IDH1 R132H protein, known as mIDH1R132, as described
previously (Capper et al, 2009).
Evaluation of immunostaining
Each section stained by anti-PROX1 antibodies was examined
under  100–400 magnifications using an Olympus light micro-
scope (UPMTVC, Olympus, Tokyo, Japan) and a coupled Leica
camera (DFC320, Leica Microsystems GmbH, Wetzlar, Germany).
Representative tumour areas, marked on each section by the
neuropathologist, were used for counting PROX1 immunopositive
cells. Areas with the highest density of immunopositive cells were
chosen. At least 200 cells were counted for each section and the
proportion of PROX1 immunopositive tumour cells was calculated.
The counts were performed independently by two of the authors
(TE and AS). All cases were anonymised before scoring and the
authors had no access to the clinical data before counting.
Both authors (TE and AS) also evaluated immunostainings by
the MIB-1 antibody, which was performed as part of the diagnostic
review. The MIB-1 antibody recognises the Ki-67 protein, which is
strongly associated with cell proliferation (Johannessen and Torp,
2006). Samples with the highest amount of Ki-67 immunopositive
tumour cells were identified and separated from samples with
lower amount of positive cells.
Evaluation of immunostaining with mIDH1R132 was performed
by one of the neuropathologists (AvD) as previously reported, and
samples were classified as either positive or negative for mutated
IDH1 protein (Capper et al, 2009).
Fluorescent in situ hybridisation
Fluorescent in situ hybridisation analysis (FISH) on paraffin
sections to study losses of the chromosomal arms 1p and 19q was
performed as described previously (Broholm et al, 2008). The
commercially purchased probes used for hybridisation were
Zytolight SPEC 1p36/1q25 and 19q13/19p13 dual colour probes
(Nordic BioSite, Ta ¨by, Sweden). Slides were assessed under a
fluorescence microscope (Olympus BX50, Olympus Deutschland
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sGmbH, Hamburg, Germany), and a minimum of 100 non-
overlapping nuclei of cells located in the tumour bulk
were evaluated for numbers of green (reference probe) and red
signals (target probe) in each hybridisation. A tumour was
considered deleted when 450% of the nuclei harboured only
one red signal of the target probe and the two green signals of the
reference probe.
Statistical analysis
The statistical calculations were performed in JMP, version 5.0.1a
(SAS Institute Inc., Cary, NC, USA). Survival curves were plotted
according to the Kaplan–Meier method (product-limit method)
and the log-rank probability test (Mantel–Cox) estimated the
prognostic value of the PROX1 expression in the univariate
analysis. The Cox proportional hazard model was used to calculate
the impact of PROX1 expression in the multivariate analysis
together with established prognostic factors. Established clinical
prognostic factors for LGG were used in the model (Pignatti
et al, 2002), as well as contrast enhancement, extent of resection,
radiotherapy and the molecular markers Ki-67, mutated IDH1
R132H protein and combined loss of 1p/19q. The level for
confounders to be removed from the model when adjusted for
variables already in the model (p-to-remove) was set to 40.1. The
natural logarithm (ln) cumulative hazard plots were made to
confirm the assumption of the proportional hazard functions. The
significant prognostic factors in the stepwise model were also
analysed as products to minimise the possibility of interaction.
RESULTS
Patient characteristics
Clinical characteristics of the 116 patients are presented in Table 1.
The mean age at the time of disease onset was 40 years. Patients
mostly presented with seizures, others with headaches and
cognitive disturbances. The majority of patients had duration of
symptoms o6 months and a good preoperative clinical status at
the time of surgery. Most common type of surgery was subtotal
tumour resection. Almost all patients had radiotherapy. Che-
motherapy was given in 22 cases and ruled out in 7 cases, but the
exact number of patients receiving chemotherapy could not be
evaluated due to insufficient follow-up data at local hospitals (not
shown).
Tumour characteristics
The characteristics of the tumours are presented in Table 2.
Histopathological diagnoses comprised astrocytomas (including
gemistocytic), oligoastrocytomas and oligodendrogliomas WHO
grade II. Most tumours were located in the frontal lobe. Others had
temporal, parietal, occipital or central location, or involved more
than one lobe. The majority of tumours was o6cm in diameter,
showed no contrast enhancement and did not cross midline
structures.
Molecular characteristics
Table 3 shows the molecular tumour profiles, summarising the
results of PROX1 protein expression, mutated IHD1 R132 protein,
combined losses of chromosomal arms 1p and 19q, that is, loss of
heterozygosity (LOH) 1p/19q, and Ki-67.
Detection of PROX1 protein PROX1 was detected in all 116 cases
and manifested as a well-defined nuclear staining. There was an
evident variability between the numbers of PROX1 immunoposi-
tive tumour cells in the different samples (Figure 1). We also found
some intra-tumoral variability in distribution of PROX1-positive
cells, as well as a minor variation in staining intensity between
different tumour cells within the same sample. We counted only
clearly positive nuclear stained cells and consequently counted
cells in tumour areas with highest number of immunopositive
cells. Results of the two independently performed counts showed
agreement (i.e., p10% difference in the proportion of positive
tumour cells assessed by the two observers) for 89 samples. For 27
cases, the inter-observer variability was 410%. We recounted
these samples and grouped them into three categories (o10%
positive cells, 10–30% positive cells and 430% positive cells).
This way we came to a consensus for all samples.
The mean percentage of positive cells for all 116 samples was
15%. Oligoastrocytomas showed a mean of 17.7%, astrocytomas of
16.5%, gemistocytic astrocytomas of 10.6% and oligodendroglio-
mas of 12.5% PROX1 immunopositive tumour cells. The propor-
tional distribution of PROX1 immunopositive tumour cells was
found similar for all three histological groups. Most samples
showed PROX1 protein in o10% of the tumour cells, the
remaining had between 10 and 30% or 430% immunopositive
tumour cells (Table 2).
Detection of mutated IDH1 R132 protein Ninety tumour samples
were found to stain for the mutated IDH1 R132H protein (Table 3).
In general, most cells stained positively for mIDH1R132 in
Table 1 Clinical characteristics of the patients with WHO grade II
gliomas included in the study (n¼116)
Parameter Number of patients (%)
Gender
Male 76 (65.5)
Female 40 (34.5)
Age
Mean (years) 40.0 years
o20 3 (2.6)
20–29 22 (19.0)
30–39 39 (33.6)
40–49 23 (19.8)
50–59 17 (14.7)
X60 12 (10.3)
Presenting symptoms
Seizures 95 (81.9)
Headache 8 (6.9)
Cognitive dysfunction 6 (5.2)
Others 7 (6.0)
Preoperative KPS
480 78 (67.3)
p80 38 (32.7)
Duration of symptoms before operation (months)
p6 72 (62.1)
7–12 12 (10.3)
13–24 12 (10.3)
424 20 (17.3)
Surgery
Biopsy only 37 (31.9)
Subtotal resection 54 (46.5)
Gross total resection 25 (21.6)
Radiotherapy
Yes 104 (89.7)
No 11 (9.5)
Uncertain 1 (0.8)
Abbreviations: WHO¼World Health Organisation; KPS¼Karnofsky Performance
Status.
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stumours that harboured the mutated IDH1 R132H protein. It has
been reported that this antibody has a high specificity to tumour
cells (Capper et al, 2009). Therefore, cells within IDH1-positive
tumours that are not stained by mIDH1R132 are considered to be
non-tumour cells.
Analysis of LOH 1p/19q by FISH Twenty-five oligodendrogliomas
showed combined losses of chromosomal arms 1p/19q. One
oligodendroglioma had 1p deletion only without loss of 19q, and
was considered as LOH 1p/19q negative. Eight oligoastrocytomas
showed combined 1p/19q loss. None of the astrocytomas in our
series was found with this chromosomal abnormality (Table 3).
Univariate survival analysis
In all, 102 of the 116 identified patients (87%) died at the end of the
study. The median follow-up time for the 14 censored patients was
14.5 years (range 10.0–22.5 years). The 5-year survival for the
whole patient sample was 58% and the 10-year survival was 32%.
Median survival was 6.2 years.
Analysis of the prognostic significance of PROX1 using the
Kaplan–Meier model showed that high PROX1 expression (430%
of the tumour cells) correlated with shorter overall survival,
compared with lower PROX1 expression (10–30%, respectively,
o10% of the tumour cells) (Figure 2A). Dichotomisation of the
variable PROX1 expression into p10% and 410% positive cells
showed that PROX1 expression 410% was associated with
statistically significant shorter overall survival (P¼0.0183, log-
rank test) (Figure 2B).
Multivariate survival analysis (n¼116)
Due to limited sample size in relation to the large number of
established prognostic markers, the stepwise exclusion of variables
was used to achieve a model with as few variables as possible in the
multivariate analyses. Both models (the ‘full model’ and the
‘stepwise model’) are presented in Table 4.
Clinical variables and survival Radiotherapy as a variable had an
inverse relation to survival that was considered to be a selection
bias, and was therefore removed from the Cox model. The
variables tumour crossing midline, contrast enhancement and
astrocytoma histology were all significant factors for poor overall
survival in the multivariate analysis. The variables higher age at
disease onset and large tumour size were not associated with
shorter overall survival.
Molecular variables and survival Multivariate analysis using the
Cox’s proportional hazard model identified the variable PROX1
expression as an independent predictor for poor overall survival,
in the full model (P¼0.0310) as well as in the stepwise model
(P¼0.0237) (Table 4). The variable IDH1 mutation was identified
as an independent predictor for longer overall survival in the full
model. Statistical analysis of Ki-67 expression (D4% vs o4%) did
not reveal any significant difference in total survival between the
two groups. Since all astrocytomas had wild-type 1p/19q status, the
impact of LOH 1p/19q as a prognostic factor was not analysed in
the whole sample, but used in a separate Cox model including
tumours with oligodendrocytic histology only (Table 5).
Survival analysis in oligodendrocytic tumours (n¼73) Multi-
variate analysis using the Cox’s proportional hazard model
identified the variable PROX1 expression as an independent
predictor for poor survival in the full model (P¼0.0275), as well as
in the stepwise model (P¼0.0269) (Table 5). As shown, the clinical
variables of younger age at disease onset together with the absence
of contrast enhancement had significantly favourable impact on
survival in this group. The variable LOH 1p/19q was identified as a
strong independent predictor for longer survival in the full model,
as well as in the stepwise model. The variable IDH1 mutation was
not identified as an independent predictor for longer survival in
the oligodendrocytic tumour group.
DISCUSSION
In the present study, we investigated the presence of PROX1
protein and its association with survival in a series of gliomas
WHO grade II. We found a correlation between high number of
PROX1 immunopositive tumour cells and poor outcome of
Table 2 Tumour characteristics of the WHO grade II gliomas included in
the study (n¼116)
Parameter Number of patients (%)
Location
Frontal 56 (48.3)
Temporal 17 (14.7)
Parietal 4 (3.4)
Occipital 1 (0.9)
Central 2 (1.7)
Corpus callosum 1 (0.9)
Multi-lobular 35 (30.1)
Histology
Astrocytoma 32 (27.6)
Gemistocytic astrocytoma 11 (9.5)
Oligoastrocytoma 34 (29.3)
Oligodendroglioma 39 (33.6)
Largest diameter (cm)
o6 84 (72.4)
X6 32 (27.6)
Contrast enhancement
Yes 52 (44.8)
No 64 (55.2)
Crossing midline
Yes 34 (29.3)
No 82 (70.7)
PROX1 expression (% positive cells)
o10% 76 (65.5)
10–30 24 (20.7)
430 16 (13.8)
Mutated IDH1 protein
Yes 90 (77.6)
No 26 (22.4)
LOH 1p/19q
Yes 33 (28.4)
No 83 (71.6)
Abbreviations: IDH1¼isocitrate dehydrogenase 1; LOH¼loss of heterozygosity.
Table 3 Molecular profiles of the tumour samples (n¼116)
Astro
(n¼32)
Gemistocytic
astro (n¼11)
Oligoastro
(n¼34)
Oligo
(n¼39)
Total
(n¼116)
X10% PROX1-
positive cells
11 3 15 11 40
Mutated IDH1
R132 protein
22 9 28 31 90
LOH 1p/19q 0 0 8 25 33
Ki-67D4% 5 1 5 12 23
Abbreviations: IDH1¼isocitrate dehydrogenase 1; LOH¼loss of heterozygosity.
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spatients. PROX1 emerged as an independent marker for survival in
the multivariate analysis, together with established molecular
prognostic factors such as LOH 1p/19q and mutated IDH1 R132H
protein. Our results suggest that PR O X 1p r o t e i ne x p r e s s i o ni san e w
molecular marker for survival in patients with grade II gliomas.
Low-grade gliomas in adults have a highly variable course of
disease. The most common presenting symptoms are epileptic
seizures. Epilepsy is often the only symptom during early disease
(Smits and Duffau, 2011). It is well known though that LGG grow
continuously and lead to neurological disability and ultimately to
death (Mandonnet et al, 2003; Schiff et al, 2007; Rees et al, 2009).
Clinical parameters correlating with prognosis such as tumour
histology, patient age, performance status, tumour size and the
presence of contrast enhancement have been used to guide
treatment decisions (Pignatti et al, 2002; Soffietti et al, 2010). In
essence, we confirmed the prognostic impact of these clinical
parameters in the present study, although evaluation by retro-
spective review of medical files is not optimal. For example,
chemotherapy (mostly used as second-line treatment in patients
with oligodendrogliomas) could not be included as a variable in
the survival analysis due to missing data. Also, contrast enhance-
ment was found more often than expected but we could not
discriminate nodular from non-nodular type of contrast enhance-
ment. Only the nodular type of contrast leaking into the tumour
has been associated with poor outcome (Pallud et al, 2009).
We found a strong correlation between favourable outcome and
LOH 1p/19q in oligodendrocytic tumours, confirming the im-
portance of this biomarker for survival. All astrocytomas in our
sample were found to be wild type for 1p and 19q, which is
consistent with previous studies on LGG (Pouratian and Schiff,
2010). In addition, the presence of mutated IDH R132H protein
was identified as an independent marker for longer survival in our
study sample (Yan et al, 2009). Mutations in IDH1 and the clinical
implications of this biomarker for gliomas have received
considerable attention lately (Von Deimling et al, 2011). Hetero-
zygous point mutations in codon 132 are frequently present in
LGG, anaplastic gliomas and secondary glioblastomas, that is,
highly malignant tumours that evolve from previously confirmed
LGG. In the vast majority of cases, IDH1 mutations affect codon
132 and in 93% of all cases they are of the R132H type (Von
Deimling et al, 2011). The development of an IDH1 R132H
mutation-specific antibody suitable for immunohistochemistry has
largely facilitated detection of mutated IDH1 protein in clinical
practice (Capper et al, 2009). As both PROX1 protein expression
and mutated IDH1 R132 protein were identified as prognostic
factors in our study, we searched for a possible correlation between
Figure 1 PROX1 protein expression in WHO grade II gliomas. Immunohistochemical staining of PROX1 (brown colour) demonstrating the variability in
the amount of PROX1 immunopositive cells between the different tumours samples. (A and B) Fibrillary astrocytoma with a relatively high respectively low
number of PROX1 expressing tumour cells. (C and D) Gemistocytic astrocytoma with a relatively high respectively low number of PROX1 expressing
tumour cells. (E and F) Oligodendroglioma with a relatively high respectively low number of PROX1 expressing tumour cells. (G and H) Oligoastrocytoma
with a relatively high respectively low number of PROX1 expressing tumour cells.
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Figure 2 (A) Kaplan–Meier estimates of postoperative survival by the
variable PROX1 protein expression for all samples with o10%, 10–30%
and 430% immunopositive tumour cells. (B) Kaplan–Meier estimates of
survival by the variable PROX1 protein expression after dichotomisation of
PROX1 into o10% and X10% immunopositive tumour cells (P¼0.0183,
log-rank test).
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sthe two biomarkers but did not find any evidence for this (data not
shown).
Statistical analysis of Ki-67 expression, with a cutoff of 4%, was
not identified as a prognostic marker in our study. This finding
is also consistent with previous reports. MIB-1 labelling has been
shown particularly useful for differentiating between diffuse and
anaplastic astrocytomas, but there is considerable overlap between
the labelling index in these different tumours and diverging cutoff
values have been proposed (Johannessen and Torp, 2006).
PROX1 is a transcription factor and a key player in the
development of the lymphatic system (Wigle and Oliver, 1999). In
the mammalian CNS, PROX1 regulates gene expression and is
involved in neurogenesis (Wigle et al, 1999; Misra et al, 2008).
Inactivation of PROX1 in the developing eye lens leads to the
downregulation of the cell cycle inhibitors p27 and p57 and
deregulation of E-cadherin (Wigle et al, 1999). Recently, we
reported on the expression patterns of PROX1 in astrocytic
gliomas. We found overexpression of PROX1 protein in high-grade
compared with low-grade gliomas and demonstrated that the
percentage of tumour cells expressing PROX1 correlated with
the malignancy grade of the tumour, which prompted further
studies with focus on the expression of PROX1 in relation to
clinical parameters and patient survival (Elsir et al, 2010).
We chose to evaluate PROX1 protein levels by scoring cells as
either positive or negative, based on our findings of relatively little
variation in staining intensity. In our previous report, we graded
immunostaining as strong positive, weak positive or negative.
In that study, samples from high-grade gliomas showed a larger
variation in staining intensity. The majority of the LGG in the
present study contained relatively few PROX1 expressing cells,
consistent with our previous findings that PROX1 protein
expression was generally higher in high-grade than in low-grade
gliomas. One could hypothesise that those tumours in the present
study with a higher proportion of immunopositive cells represent
a more advanced, less differentiated phenotype than their
counterparts with relatively low PROX1 expression. Although still
consistent with the histopathological diagnosis of WHO
grade II glioma, such tumours displaying a high proportion of
Table 4 Cox’s proportional hazard model estimating the prognostic impact of PROX1 expression and of established prognostic factors for LGG on
survival (n¼116)
Full model Stepwise model
Prognostic factor Risk ratio Confidence limits P-value Risk ratio Confidence limits P-value
Clinical variables
Age at onset o40 vs X40 years 1.24 0.87–187 0.3167 — — —
Performance status KPS 480 vs p80 0.95 0.58–1.60 0.8380 — — —
Tumour size X6 vs o6cm 1.37 0.83–2.21 0.2184 — — —
Tumour crossing midline Yes vs no 1.71 1.09–2.67 0.0211 1.71 1.11–2.61 0.0161
Contrast enhancement Yes vs no 1.62 1.06–2.47 0.0248 1.52 1.01–2.28 0.0446
Histology A vs OA/O 1.22 0.99–1.51 0.0624 1.22 1.00–1.50 0.0557
Extent of resection GTR vs not 0.75 0.43–1.27 0.2951 — — —
Molecular variables
Ki-67 expression o4% vs D4% 0.93 0.51–1.65 0.8143 — — —
IDH1 mutation Yes vs no 0.57 0.35–0.95 0.0313 0.61 0.39–1.02 0.0575
PROX1-positive cells X10% vs o10% 1.61 1.04–2.47 0.0310 1.63 1.07–2.45 0.0237
Abbreviations: KPS¼Karnofsky performance status; A¼astrocytoma; OA¼oligoastrocytoma; O¼oligodendroglioma; GTR¼gross total resection; IDH¼isocitrate
dehydrogenase; LGG¼low-grade gliomas. Factors removed from the model using the backwards exclusion method (p-to-remove 40.10): Performance status (at step 1,
P¼0.8380), Ki-67 expression (at step 2, P¼0.8627), age at onset (at step 3, P¼0.3101), extent of resection (at step 4, P¼0.2742), tumour size (at step 5, P¼0.1057).
Table 5 Cox’s proportional hazard model estimating the prognostic impact of PROX1 expression and of established prognostic factors on survival in
patients with oligodendrogliomas and oligoastrocytomas WHO grade II (n¼73)
Full model Stepwise model
Prognostic factor Risk ratio Confidence limits P-value Risk ratio Confidence limits P-value
Clinical variables
Age at onset o40 vs X40 years 2.09 1.14–3.83 0.0177 2.11 1.13–3.85 0.0144
Performance status KPS 480 vs p80 0.76 0.38–1.56 0.4474 — — —
Tumour size X6 vs o6cm 1.79 0.91–3.41 0.0892 1.81 0.95–3.37 0.0712
Tumour crossing midline Yes vs no 1.78 0.95–3.27 0.0720 1.76 0.95–3.21 0.0722
Contrast enhancement Yes vs no 2.37 1.32–4.31 0.0040 2.28 1.28–4.09 0.0052
Histology OA vs O 1.39 1.02–1.92 0.0395 1.32 0.98–1.79 0.0683
Extent of resection GTR vs not 0.86 0.40–1.71 0.6689 — — —
Molecular variables
Ki-67 o4% vs D4% 1.97 0.90–4.11 0.0883 2.02 0.95–4.07 0.0662
IDH1 mutation Yes vs no 0.72 0.36–1.53 0.3786 — — —
LOH 1p/19q Yes vs no 1.62 1.15–2.31 0.0052 1.77 1.31–2.44 0.0002
PROX1-positive cells X10% vs o10% 2.00 1.08–3.70 0.0275 1.98 1.08–3.63 0.0269
Abbreviations: KPS¼Karnofsky performance status; OA¼oligoastrocytoma; O¼oligodendroglioma; GTR¼gross total resection; IDH¼isocitrate dehydrogenase; LOH¼loss
of heterozygosity; WHO¼World Health Organisation. Factors removed from the model using the backwards exclusion method (p-to-remove 40.10): Extent of resection (at
step 1, P¼0.6689), performance status (at step 2, P¼0.3997), IDH1 mutation (at step 3, P¼0.5105).
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anaplastic gliomas compared with tumours with few PROX1
expressing tumour cells. Although the histology of LGG is far less
heterogeneous than in high-grade gliomas, LGG are likely to
represent clinically different stages of evolution ranging from
indolent to more aggressive variants. To be able to foresee early
progression of these tumours would help extensively in clinical
practice, where more aggressive treatment should be postponed for
patients with low risk for tumour progression (Piepmeier, 2009;
Soffietti et al, 2010)
Within the limitations of the study design, we made an effort to
provide reproducible results and to avoid flaws that commonly
occur in retrospective data collection. Samples were identified
by searching clinical records of patients operated between 1982
and 1999, and were selected on the basis of the availability of
good quality paraffin-embedded tumour blocks only. Samples
were reviewed by independent neuropathologists who marked
representative tumour areas on the back of the slides to be used for
evaluation of immunostaining. Follow-up time of the cohort was
long, with a minimum of 10 and up to 25 years.
In conclusion, the present findings support our previous work
showing that higher PROX1 protein expression in gliomas reflects
a more malignant phenotype. Our study also promotes PROX1 as
a prognostic marker for WHO grade II gliomas. Further studies
on the functional role of PROX1 as a biomarker in gliomas are
warranted.
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